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Abstract The objective of the present study was to
describe a new model of the cost-effectiveness of treatment
of generalized anxiety disorder (GAD) and its application
to a comparison of pregabalin versus venlafaxine extended-
release (XR) from a Spanish healthcare perspective.
Microsimulation techniques, including Hamilton Anxiety
Scale (HAM-A) score, number of weeks with minimal or
no anxiety (HAM-A B 9), and quality-adjusted life-years
(QALYs), were used to predict treatment outcomes for
patients with moderate-to-severe GAD who would be
treated with pregabalin vs venlafaxine XR. Expected levels
of healthcare utilization and unit cost of care are derived
from Spanish published sources. We express cost-effec-
tiveness alternatively in terms of incremental cost per
additional week with minimal or no anxiety, and incre-
mental cost per QALY gained [in 2007 Euros (€)].
Considering costs of drug treatment only, the incremental
cost [mean (95% conﬁdence interval)] of pregabalin (vs
venlafaxine XR) would be €96 (€86, €107) per additional
week with minimal or no anxiety, and €32,832 (€29,656,
€36,308) per QALY gained. When other medical care costs
are considered, cost-effectiveness ratios decline to €70
(€61, €80) per additional week with no or minimal anxiety,
and €23,909 (€20,820, €27,006) per QALY gained. We
conclude that, using a new microsimulation model of the
treatment of GAD, pregabalin appears to be cost-effective
vs venlafaxine XR in a Spanish healthcare setting.
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Introduction
Anxiety disorders are considered the most prevalent type of
psychiatric disorder, with generalized anxiety disorder
(GAD) being the most common in the primary care setting
[1]. Large epidemiologic studies have reported lifetime
rates of GAD ranging from 2.8 to 5.1% [2–4]. The most
common symptoms of GAD are both physical and psy-
chological. Somatic complaints include chest pain, irritable
bowel symptoms, headache, hyperventilation, fatigue,
insomnia, joint pain, and palpitations [1]. Psychological
complaints typically include pervasive and uncontrollable
persistent worry and tension about daily life events lasting
more than 6 months. Patients with GAD are more likely
than other patients to present with medical comorbidities,
seek medical care, and undergo extensive medical testing
(to rule out other pathologies), making GAD a challenging
medical condition to recognize [5, 6]. The burden of the
disease is also notable in terms of restrictions on patients’
ability to carry out their daily activities. Reductions in
patients’ health-related quality of life and well-being [1, 7]
have been reported to be comparable in magnitude to those
accompanying major depressive disorders.
Benzodiazepines have been shown to be useful for rapid,
short-tem relief of somatic symptoms of GAD [8], and they
are often used to help alleviate the restlessness associated
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potential for dependency, however, these agents are
restricted to short-term use in many countries. Effective
pharmacotherapies that may be used on a long-term basis
in patients with GAD include antidepressants, such as
paroxetine and escitalopram—both selective serotonin re-
uptake inhibitors (SSRIs)—and extended-release (XR)
venlafaxine, a serotonin-norepineprhine reuptake inhibitor.
If a patient’s initial response to treatment with these agents
is positive, it is recommended that therapy be continued for
6 months to 1 year, and then tapered off [9]. As it is rec-
ognized that many patients with GAD are undertreated, and
that the disease imposes a substantial economic burden on
patients, for the healthcare system, and society at large,
successful treatment of symptoms of GAD may confer
substantial beneﬁts. While the cost of chronic pharmaco-
therapy for GAD is not negligible, few formal economic
evaluations of these agents have been reported in the
published literature. The cost-effectiveness of venlafaxine
XR (vs diazepam) was examined recently from the per-
spective of the United Kingdom’s National Health Service
using a decision-analytic model [10]. The authors con-
cluded that while ﬁrst-line treatment with venlafaxine XR
was more expensive, it was clinically more effective,
reduced the overall cost of consultations to general prac-
titioners and mental health-care providers, and was cost-
effective in the management of non-depressed patients
suffering from GAD. Another UK study suggested that
ﬁrst-line treatment with escitalopram may lead to higher
treatment response rates and overall cost savings compared
to ﬁrst-line treatment with paroxetine [11].
In this study, we report on a new pharmacoeconomic
model of GAD treatment that we developed to support
medical decision-making in this patient population. To
illustrate its use, we used the model to estimate the cost-
effectiveness of pregabalin (an anticonvulsant agent indi-
cated for the treatment of GAD in Europe) vs venlafaxine
XR, using data from the Pregabalin Efﬁcacy in Anxiety
Clinical Evaluation (PEACE) trial [12] and resource utili-
zation data from Spain.
Methods
Model overview
We developed a patient-level simulation model to estimate
clinical and economic outcomes of pharmacotherapy in
patients with GAD. A similar modeling approach has been
employed in two prior published cost-effectiveness evalu-
ations of pregabalin in the treatment of neuropathic pain
and epilepsy, respectively [13, 14]. Patients in the model
were assumed to have moderate-to-severe chronic anxiety
at therapy initiation, consistent with the characteristics of
study subjects in most clinical trials in this patient popu-
lation. To characterize anxiety symptoms in patients with
GAD, the model uses the Hamilton Anxiety Scale (HAM-
A) [15]. The HAM-A is a clinician-rated symptom scale
designed to quantify the severity of anxiety symptoms and
to assess response to therapeutic interventions. The
instrument consists of 14 items (anxious mood, tension,
fears, insomnia, intellectual impairment, depressed mood,
somatic muscular and sensory complaints, cardiovascular,
respiratory, genitourinary and autonomic symptoms, and
patient’s behavior at interview), each deﬁned by a series of
symptoms. Each item is scored on a 0–4 scale. The possible
score range on the HAM-A is therefore 0–56.
In the model, we allow HAM-A scores to vary with
treatment from patient to patient. The model designates
HAM-A scores B9 as ‘‘no or minimal anxiety’’; 10–15, as
‘‘mild anxiety’’; 16–24, as ‘‘moderate anxiety’’; and C25,
as ‘‘severe anxiety’’. While (to the best of our knowledge)
these categorizations have not been validated clinically,
they have been employed by others [16, 17]. The value of
using time without symptoms to compare treatments of
chronic symptomatic diseases has long been recognized in
a variety of medical conditions, including pain, depression,
and epilepsy [18–22].
The model focuses attention on a hypothetical cohort of
1,000 patients with GAD, and simulates their symptoms of
anxiety (as measured by their HAM-A scores) on a weekly
basis up to 1 year (shorter time horizons also may be
employed in the model). In the model, patients are ﬁrst
assigned an average pre-treatment HAM-A score, based on
the distribution of HAM-A scores in the clinical trial
(Fig. 1). The model then projects, for each patient in the
cohort, the impact of therapy on weekly HAM-A scores,
based on the expected change from baseline. Expected
changes in HAM-A scores are permitted to vary from week
to week (e.g., they may be lower during the ﬁrst weeks
following initiation of therapy); they also are permitted to
vary from patient to patient, based on assumed variability
of the weekly percentage change in HAM-A scores with
treatment. For each treated patient, expected HAM-A
scores are derived by multiplying the pretreatment HAM-A
score by the expected percentage change in HAM-A score
by week. After expected weekly HAM-A scores are
assigned to each patient in the model, health-state utilities
are then assigned for each week. The model considers the
impact of therapy on GAD symptoms only; the potential
effect of treatment on concomitant depressive symptoms, if
present, is not considered. The impact of treatment on lost
productivity due to GAD-related disability is also (con-
servatively) not considered.
The model allows for the possibility that patients may
discontinue therapy if they experience lack of efﬁcacy and/
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123or side effects. If therapy discontinuation is permitted,
patients may switch to another treatment or remain
untreated. Patients also may be assumed to initiate care
with their primary care provider or a specialist, and receive
additional health-care services (e.g., specialists visits, lab-
oratory tests, inpatient).
The model calculates a variety of summary measures of
patient outcome, including the expected HAM-A score
with treatment (mean over time), the expected number of
weeks with no or minimal anxiety (HAM-A B 9), mild
anxiety (10–15), moderate anxiety (16–24), and severe
anxiety (C25), respectively, and quality-adjusted life-years
(QALYs). These measures of clinical outcome are then
combined with estimates of utilization and cost (of phar-
macotherapy and, optionally, healthcare services) to cal-
culate the cost-effectiveness of the treatments considered.
The perspective of the analyses is that of a third-party
payer. Utilization of healthcare services is assumed in the
model to vary in relation to HAM-A scores. Cost-effec-
tiveness is calculated alternatively in terms of the incre-
mental cost per additional week with no or minimal
anxiety, and the incremental cost per QALY gained.
To illustrate use of the model, we undertook an analysis
comparing pregabalin and venlafaxine XR. Pregabalin is an
anticonvulsant agent ([S]-3-[aminomethyl]-5-methylhexa-
noic acid) that is approved in Europe for the treatment of
GAD; venlafaxine XR is a widely used SNRI that has
shown substantial efﬁcacy in patients with anxiety disor-
ders. We based this comparison on data from the PEACE
study [12], an 8-week, three-arm, multicenter, randomized,
double-blind clinical trial of pregabalin (300–600 mg/day),
venlafaxine XR (75–225 mg/day), and placebo in patients
with GAD that was designed to address onset of efﬁcacy,
and which used ﬂexible dosing schemes to reﬂect condi-
tions of typical clinical practice. Approximately 130
patients were randomized in equal proportions to the three
treatment groups. Mean (± SD) daily dose was 348 (± 85)
mg for pregabalin and 102 (± 33) mg for venlafaxine.
Versus placebo, pregabalin resulted in a statistically sig-
niﬁcant decrease from baseline to endpoint in HAM-A
scores (P = 0.028); the difference between venlafaxine
XR and placebo was not statistically signiﬁcant (the trial
was not powered to detect a difference between the two
active comparators). Pregabalin and venlafaxine were both
generally well tolerated.
Model estimation
At model entry, each patient in the hypothetical cohort was
randomly assigned an initial HAM-A score by sampling
(with replacement) from the actual distribution of HAM-A
scores at study entry in the PEACE trial (data on ﬁle,
Pﬁzer). Based on this assignment, 25% of patients were
estimated to have moderate anxiety (HAM-A score 16–24)
at study entry; the remainder were estimated to have severe
anxiety (HAM-A score C25) (Table 1).
The expected weekly percentage changes in the HAM-A
score over 8 weeks with pregabalin and venlafaxine XR
were obtained by sampling (with replacement) from the
Cohort
of patients with 
GAD
Expected HAM A Expected Change in HAM A
Week 0
Pre-treatment HAM-A
(µ=x)
Expected HAM-A
E HAM-A=1-( + )(µ± ) Utility/Cost Week 2 Expected Change in HAM-A
with treatment ( + ) End F/U
-
E HAM-A=1-( + )(µ± ) Utility/Cost Week 1
-A
with treatment ( + )
….
Expected HAM-A
E HAM-A=1-( + )(µ± ) Utility/Cost Week 12 Expected Change in HAM-A
with treatment ( + ) End F/U
Fig. 1 Schematic of patient-
level simulation model
Table 1 Pre-treatment HAM-A Hamilton Anxiety Scale
HAM-A (% of patients)
a
B9 0.0
10–15 0.0
16–24 25.5
C25 74.5
a PEACE (Pregabalin Efﬁcacy and Anxiety Clinical Evaluation)
clinical trial (data on ﬁle, Pﬁzer)
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subjects in the PEACE study who were randomized to
receive these agents (data on ﬁle, Pﬁzer); results are
summarized in Table 2. As data were not available beyond
8 weeks, treatment beneﬁt (i.e., mean percentage change in
HAM-A) was assumed to be maintained from week 8 until
1 year. Alternative time horizons (8 weeks, 6 months)
were examined in sensitivity analyses. The distribution of
the change in HAM-A score with therapy was assumed
to be left-truncated normal (i.e., percentage reduction in
HAM-A with therapy could not be higher than 100%),
based on empirical observation of patient-level data from
the clinical trial.
In our basecase analyses, we assumed that patients would
not discontinue therapy irrespective of its efﬁcacy or the
occurrence of side effects. In sensitivity analyses, we
assumed that patients might discontinue therapy for these
reasons, based on data from the PEACE study (Table 3). All
patients who were assumed to discontinue therapy in sen-
sitivity analyses were assumed to switch to treatment with
paroxetine 20 mg/day, and to remain on such therapy for
the remainder of time in the model. Alternative assumptions
(0, 25, 50%) with respect to the rate of switching to par-
oxetine were examined in sensitivity analyses. All patients
switching to paroxetine were assigned a mean weekly per-
centage change of 50%, based on published data [23–26].
Health-state utilities were assigned to patients on a
weekly basis, based on their predicted severity of anxiety
(i.e., no or minimal, mild, moderate, severe), using values
from the EQ-5D Weighted Health Index (WHI) [27]
obtained from a cross-sectional study of 456 patients with
GAD from a representative randomly selected sample of
134 primaryhealthcenters inSpain [28].Utilityvalueswere
estimated in that study in relation to the severity of anxiety
symptoms (as measured by HAM-A scores) (Table 3).
The costs of pregabalin (Lyrica
) and venlafaxine XR
(Vandral Retard
) therapy were estimated using published
price lists [29], assuming average daily dosages of 348 mg
and 102 mg, respectively, based on data from the PEACE
study; the reference price was employed for paroxetine
(20 mg/day). The daily dosages of these medications are
consistent with those recommended in product labeling
information in Spain. Expected levels of healthcare utili-
zation were derived from the above-described cross-sec-
tional study, and included use of routine outpatient visits
(primary care, specialists, other providers), emergency
room visits, selected laboratory tests, and inpatient days
(Table 4). Utilization of healthcare services in the study
was estimated in relation to the severity of anxiety symp-
toms (as measured by HAM-A scores). Estimates of the
costs of services were derived from a publicly available
Spanish database [30] (Table 5). All costs are reported in
2007 Euros (€).
Analyses
The model was estimated using Monte Carlo simulation
techniques[31,32],assumingacohortof1,000patientswith
moderate-to-severe GAD symptoms. During simulation,
Table 2 HAM-A score change (vs pre-treatment) with therapy (%)
Therapy Mean SD SE
Pregabalin 300–600 mg/day
a
Week 1 -27.2 20.6 2.22
Week 2 -39.8 22.1 2.38
Week 3 -45.7 24.1 2.60
Week 4 -51.4 24.1 2.60
Week5 -51.4 24.1 2.60
Week 6 -57.4 26.5 2.86
Week 7 -57.4 26.5 2.86
Weeks 8–52 -61.4 26.0 2.81
Venlafaxine 75–225 mg/day
a
Week 1 -18.7 20.2 2.08
Week 2 -34.6 24.3 2.51
Week 3 -43.0 24.9 2.56
Week 4 -48.3 25.9 2.67
Week 5 -48.3 25.9 2.67
Week 6 -51.6 26.0 2.69
Week 7 -51.6 26.0 2.69
Weeks 8–52 -52.6 26.0 2.68
Paroxetine 20 mg/day (weekly)
b -50.0 n/a n/a
a PEACE (Pregabalin Efﬁcacy and Anxiety Clinical Evaluation)
clinical trial (data on ﬁle, Pﬁzer)
b References [23–26]
Table 3 Other clinical parameters
Parameter Value
Therapy discontinuation over 8 weeks (% of patients)
a
Due to side effects
Pregabalin 300–600 mg/day 12.4
Venlafaxine 75–225 mg/day 17.6
Due to lack of efﬁcacy
Pregabalin 300–600 mg/day 3.3
Venlafaxine 75–225 mg/day 3.2
Health-state utility (mean), by HAM-A score interval
b
B9 0.84
10–15 0.71
16–24 0.68
C25 0.53
a PEACE (Pregabalin Efﬁcacy and Anxiety Clinical Evaluation)
clinical trial (data on ﬁle, Pﬁzer)
b Rovira [28] and data on ﬁle (Pﬁzer)
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a time, yielding expected values for each patient in the
cohort; patients were assumed to be treated alternatively
with pregabalin and venlafaxine XR. Summarization of the
outcomes of interest across all patients in the cohort yielded
expected values for each treatment group. Measures of
clinical outcome were then combined with estimates of
the cost of pharmacotherapy and medical-care services
to calculate the cost-effectiveness of pregabalin versus
venlafaxine XR. Cost-effectiveness was examined alterna-
tively in terms of the incremental cost per additional week
with no or minimal anxiety, and the incremental cost per
QALY gained. Incremental cost-effectiveness was exam-
ined under two alternative primary scenarios—one that
considered only the cost of pharmacotherapy, and another
that included costs of medical-care services along with the
cost of pharmacotherapy.
Deterministic one-way sensitivity analyses were under-
taken by varying selected assumptions and parameter
estimates for which probability distributions were unknown
or inapplicable, including: (1) modeling time horizon;
(2) therapy discontinuation due to lack of efﬁcacy and/or
side effects; (3) rates of switching to paroxetine; (4) health-
state utilities by HAM-A interval (alternatively, 25 and
75% quartile values from the Spanish cross-sectional study,
and EQ-5D values from the PEACE clinical trial);
(5) utilization of medical-care services; and (6) the costs of
medical-care services. One-way sensitivity analyses were
conducted for the incremental cost per QALY gained only.
Probabilistic sensitivity analyses (i.e., second-order
Monte Carlo simulations) were undertaken to address
uncertainty with respect to the weekly mean percentage
changes in HAM-A scores with pregabalin and venlafaxine
XR respectively. We ran the model for 100 samples of
1,000 patients each in these analyses. A left-truncated
normal distribution was assumed for the weekly expected
percentage changes in the HAM-A during simulation (i.e.,
percentage mean reduction in HAM-A with therapy could
not be higher than 100%, based on empirical observation of
patient-level data from the clinical trial). Cost-effective-
ness acceptability curves reﬂecting the probability that
pregabalin would be cost-effective (vs venlafaxine XR) at
various thresholds of willingness to pay also were gener-
ated under alternative analytical scenarios.
Results
Estimates of expected clinical outcomes and costs in
patients with GAD treated with pregabalin vs venlafaxine
XR, respectively, are reported in Table 6. The average
HAM-A score at therapy initiation was estimated to be
27.1; the estimated mean HAM-A score at the end of
1 year was 10.6 for patients treated with pregabalin and
12.8 for those treated with venlafaxine XR. The expected
total number of weeks (over 1 year) with no or minimal
anxiety (HAM-A B9) was 13.5 for pregabalin and 4.3 for
venlafaxine XR. Pregabalin was also estimated to yield
reductions in the number of weeks with mild anxiety
(HAM-A 10–15), moderate anxiety (HAM-A 16–24), and
severe anxiety (HAM-A C25). The estimated mean number
of QALYs gained with pregabalin therapy (over 1 year)
Table 4 Utilization of direct medical-care services, by HAM-A score
intervals among patients with generalized anxiety disorder (GAD) in
Spain
a
Parameter HAM-A score
B9 10–15 16–24 C25
Primary care visits (mean) (per month) 0.44 1.03 1.26 1.80
Specialist visits (mean) (per month)
Psychiatrist 0.42 0.48 0.48 0.49
Psychologist 0.48 0.52 1.03 1.37
Emergency room 0.14 0.26 0.37 0.56
Other 0.33 0.37 0.58 0.52
Other outpatient services (mean) (per month)
Blood counts 0.35 0.38 0.50 0.43
Electrocardiogram 0.33 0.35 0.33 0.18
Thyroid function 0.33 0.33 0.36 0.35
Inpatient days (mean) 0.12 0.18 0.37 0.49
a Source: Rovira et al. [28] and data on ﬁle, Pﬁzer
Table 5 Estimates of unit costs € (Spain)
Mean (€)
Primary care visit
a 15.3
Specialist visit
a
Psychiatrist 81.3
Psychologist 35.0
Emergency room 111.6
Other 48.4
Other outpatient services
a
Blood count 20.5
Electrocardiogram 13.5
Thyroid function 9.0
Inpatient day
a 231.7
Cost of medication (per day)
b
Pregabalin 300–600 mg 4.5
Venlafaxine 75–225 mg 2.2
Paroxetine 20 mg 0.7
a Oblikue Consulting 2007
b Catalogo del Consejo General de Colegios Farmaceuticos 2007,
(cost estimated based on pregabalin 348 mg/day, venlafaxine
102 mg/day)
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cost of pharmacotherapy over 1 year was estimated to be
€1,664 for pregabalin, and €780 for venlafaxine XR. Mean
costs of medical-care services were estimated to be €2,207
for patients receiving pregabalin and €2,454 for those
receiving venlafaxine XR; the difference was attributable
to expected differences in visits to primary care physicians,
mental health-care providers, laboratory tests, and inpatient
days. Total estimated costs over 1 year were €3,871 for
pregabalin and €3,234 for venlafaxine XR.
The incremental cost of pregabalin therapy (vs venla-
faxine XR) per additional week with no or minimal anxiety
was [mean (95% CI)] €96 (€86, €107) (Table 7) when
pharmacotherapy costs only were considered; the corre-
sponding incremental cost per QALY gained was €32,832
(€29,656, €36,308). When costs of all medical-care ser-
vices were included, corresponding ratios were €70 (€61,
€80) per additional week with no or minimal anxiety, and
€23,909 (€20,820, €27,006) per QALY gained.
Findings from one-way deterministic sensitivity analy-
ses on key model assumptions and parameter estimates are
reported in Table 8. In these analyses, the incremental cost
per QALY gained for pregabalin therapy ranged from
€21,836 to €67,928 under varying assumptions. The ratio
was low when other cost offsets were included, when
therapy discontinuation was allowed, and when patients
were assumed to return to an untreated health state, and
when 75% quartile values were employed for health-state
utilities for each of the model deﬁned HAM-A score
intervals (cost of pharmacotherapy only); it was highest
when the modeling time horizon was limited to 8 weeks
(the duration of follow-up in the PEACE trial). Ratios also
increased when 25% quartile values were employed as
estimates of health-state utilities. Estimates were also
sensitive to changes in the assumed rate of switching to
paroxetine when assumptions of therapy discontinuation
were employed. Findings were not particularly sensitive to
increases in the assumed risk of therapy discontinuation
due to side effects or lack of efﬁcacy, the use of a 6-month
modeling time horizon, and changes in estimates of
resource utilization and the unit costs of medical-care
services (cost offsets scenario). In probabilistic sensitivity
analyses, estimates of the cost-effectiveness of pregabalin
(vs venlafaxine XR) were in the vicinity of €30,000 per
QALY gained, an arbitrarily accepted threshold value for
willingness to pay [33] (Fig. 2).
Table 6 Expected clinical and
economic outcomes over 1 year
among patients with GAD
(Spain)
GAD Generalized anxiety
disorder, HAM-A hamilton
anxiety scale, QALY quality-
adjusted life-year
Parameter Pregabalin
300–600 mg/day
Venlafaxine
75–225 mg/day
Difference
HAM-A score (mean)
Pre-treatment 27.1 27.1 0.0
Post-treatment 10.6 12.8 –2.1
Weeks with anxiety state (HAM-A score)
None or minimal (B9) 13.5 4.3 9.2
Mild (10–15) 34.6 38.5 –3.9
Moderate (16–24) 3.2 8.2 –5.1
Severe (C25) 0.7 1.0 –0.3
Quality-adjusted life-years (QALYs) (mean) 0.740 0.713 0.027
Cost (€) (mean)
Pharmacotherapy 1,664 780 884
All other medical-care services
Primary care visits 152 188 –36
Specialists 1,316 1,425 –109
Inpatient days 538 634 –96
Other 201 207 –6
Total medical-care services 2,207 2,454 –247
Total 3,871 3,234 637
Table 7 Expected cost-effectiveness of pregabalin (300–600 mg/
day) vs venlafaxine (75–225 mg/day) at 1 year among patients with
GAD (Spain)
Parameter Mean (95% CI) (€)
Incremental cost per additional week with none or minimal anxiety
(HAM-A B 9)
Cost of pharmacotherapy only 96 (86, 107)
All direct medical-care costs 70 (61, 80)
Incremental cost per QALY gained
Cost of pharmacotherapy only 32,832 (29,656, 36,308)
All direct medical-care costs 23,909 (20,820, 27,006)
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Scenario D Cost/D QALY (2007 €)
[mean (95% CI)]
Scenario 1: Cost of pharmacotherapy only 32,832 (29,656, 36,308)
Model time horizon
1 8 weeks (trial duration) 67,928 (38,833, 136,000)
2 24 weeks 36,779 (31,745, 42,062)
Therapy discontinuation for all reasons, and switch to paroxetine (% of patients)
30 24,857 (21,147, 32,237)
42 5 27,286 (22,808, 34,921)
55 0 29,876 (24,377, 37,270)
6 100 34,844 (30,526, 40,514)
7 Discontinuation due to side effects (1.5 9 basecase) (pregabalin) and 100% switch to paroxetine
if discontinuation
32,936 (28,547, 37,929)
8 Discontinuation due to lack of efﬁcacy (1.5 9 basecase) (pregabalin) and 100% switch to paroxetine
if discontinuation
34,223 (29,896, 39,961)
9 Health-state utility, by HAM-A score interval
Spanish cross-sectional study (25% quartile values)
HAM-A score\9 (0.74), 10–15 (0.65), 16–24 (0.62), C25 (0.38) 43,169 (38,603, 47,153)
Spanish cross-sectional study (75% quartile values)
HAM-A score\9 (1.00), 10–15 (0.80), 16–24 (0.79), C25 (0.74) 24,041 (21,400, 26,430)
PEACE study
HAM-A score\9 (0.83), 10–15 (0.71), 16–24 (0.61), C25 (0.36) 26,766 (24,423, 29,328)
Scenario 2: All cost of medical-care services 23,909 (20,820, 27,006)
Visits, primary care (#)
10 9 0.5 basecase 24,561 (21,449, 27,807)
11 9 1.5 basecase 24,573 (22,000, 27,438)
Visits, specialists (#)
12 9 0.5 basecase 31,876 (28,808, 35,484)
13 9 1.5 basecase 21,981 (19,477, 21,213)
Other outpatient services (#)
14 9 0.5 basecase 35,993 (33,131, 39,393)
15 9 1.5 basecase 21,963 (19,433, 25,467)
Inpatient days (#)
16 9 0.5 basecase 25,638 (22,168, 28,894)
17 9 1.5 basecase 21,836 (18,880, 25,197)
Cost visits, primary care
18 9 0.5 basecase 24,323 (21,443, 27,576)
19 9 1.5 basecase 22,987 (20,112, 27,479)
Cost visits, specialists
20 9 0.5 basecase 25,471 (22,651, 28,092)
21 9 1.5 basecase 23,909 (20,820, 27,006)
Cost other outpatient services
22 9 0.5 basecase 24,071 (20,948, 27,769)
23 9 1.5 basecase 23,783 (20,541, 28,335)
Cost inpatient days
24 9 0.5 basecase 24,788 (22,266, 27,813)
25 9 1.5 basecase 19,829 (17,173, 23,162)
QALY quality-adjusted life-year
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In this paper, we report on a simulation model that we
developed to estimate expected clinical and economic
outcomes associated with the treatment of GAD, which
may be used to support therapeutic decision making in this
patient population. When we used our model to examine
the cost-effectiveness of pregabalin vs venlafaxine XR in
the treatment of GAD in a Spanish setting, we found that
pregabalin would cost an estimated €96 (€86, €107) per
additional week with no or minimal anxiety, and €32,832
(€29,656, €36,308) per QALY gained (both over 1 year).
When estimates of potential offsets in the utilization of
medical-care services were included, corresponding esti-
mates were €70 (€61, €80) per additional week with no or
minimal anxiety, and €23,909 (€20,820, €27,006) per
QALY gained. The incremental cost per QALY gained was
€30,000 or less across most scenarios in sensitivity
analyses.
To the best of our knowledge, only two prior studies
have used models to examine the cost-effectiveness of
pharmacotherapy in patients with GAD [10, 11]; both were
conducted in the United Kingdom (UK). Differences in
analytical approach, outcome measures, time horizons, and
assumptions employed in these two studies preclude
comparisons with our ﬁndings. Guest and colleagues [10]
examined the cost-effectiveness of venlafaxine XR vs
diazepam over 6 months from the perspective of the UK’s
National Health Service. They used a deterministic deci-
sion-analytic model and reported an estimate of the
incremental cost per additional patient successfully treated
with venlafaxine XL (vs diazepam) (GPB £380), and the
incremental cost for each additional patient in whom a
relapse would be avoided (£295) (both in 2000/2001
prices); they concluded that starting treatment with venla-
faxine rather than diazepam was more effective clinically
and more cost-effective for managing non-depressed
patients with GAD in the UK. The Investigator’s Clinical
Global Impression (CGI) improvement score was used as
the key clinical measure in the model, but the authors
recognized that the CGI might be less robust than HAM-A
scores. Jorgenssen and colleagues [11] used a similar
model and reported higher rates of ﬁrst-line treatment
success and lower rates of discontinuation due to adverse
events over 9 months for patients treated with escitalopram
(vs paroxetine), as well as cost savings of £1,408 (at 2004
price levels) from a societal perspective. Treatment success
and relapse were deﬁned in the model using the CGI alone
or in combination with HAM-A threshold values and
therapy discontinuation due to lack of efﬁcacy. The authors
did not report estimates of the cost-effectiveness of escit-
alopram vs paroxetine. In both models, assumptions of
therapy discontinuation and switching to another pharma-
cotherapy for GAD (i.e., paroxetine, diazepam) were
employed.
A few key aspects of our model should be noted. One
particular strength is its stochastic (as opposed to deter-
ministic) nature, which takes into consideration the
uncertainty inherent in estimates of the average change in
HAM-A scores with treatment. Second, measures of clin-
ical effectiveness employed in our model include time (i.e.,
weeks) with no or minimal anxiety in addition to QALYs.
While use of QALYs allows comparisons with ﬁndings
from pharmacoeconomic evaluations of interventions for
other medical conditions, use of ‘‘time without symptoms’’
may best reﬂect favorable clinical outcomes from the
patient’s perspective [18–22]. We believe that our study is
the ﬁrst to report estimates of the cost-effectiveness of
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Third, while including all relevant costs and consequences
of therapy in health-economic evaluations is often recom-
mended, successful treatment is often assumed to result in
reduced utilization of medical-care services (and some-
times indirect cost savings), which typically offset the cost
of the intervention. Because we believe there is signiﬁcant
uncertainty with respect to the expected impact of effective
pharmacotherapy on GAD-related medical-care services,
our model permits examination of economic beneﬁts
alternatively considering the cost of pharmacotherapy only
and including potential offsets in the utilization and cost of
other medical-care services. Taken together, these esti-
mates probably represent reasonable ‘‘conservative’’ and
‘‘liberal’’ boundaries on the economic impact of pharma-
cotherapy for GAD.
Important limitations of our approach also should also
be noted. First, the maximum time horizon in our model is
1 year. During model development, we thought that we
could neither establish a reasonable treatment algorithm for
patients over a longer time horizon (e.g., 5 years, lifetime),
nor accurately estimate the expected change in HAM-A
scores with follow-on therapy conditional upon success or
failure of prior therapies over time. Use of a 1-year time
horizon is also consistent with current recommendations
regarding the treatment of GAD (i.e., 6 months–1 year, and
then taper) [9]. Our model, however, permits examination
of cost-effectiveness for shorter time horizons, including
the typical duration of clinical trials (e.g., 8–12 weeks).
Second, because the duration of follow-up in the PEACE
study was 8 weeks, and in the absence of long-term data,
we assumed that the efﬁcacy of pregabalin and venlafaxine
XR observed in the trial would be maintained over 1 year;
this may or may not be an accurate depiction of reality.
Third, in our primary analyses, patients were assumed to be
treated over 1 year assuming without treatment discontin-
uation due to lack of efﬁcacy or side effects. This approach
obviated the need to specify a follow-on treatment strategy.
While this may be unrealistic, we believe it provides a
framework for interpretation of the beneﬁts of the therapies
of interest that is not confounded by assumptions regarding
the sequence of subsequent therapies that patients might
receive and their efﬁcacy in this context. However, we did
examine the impact of therapy discontinuation and alter-
native switching rates in sensitivity analyses. The cost-
effectiveness of pregabalin therapy improved somewhat
when we assumed that therapy discontinuation due to lack
of efﬁcacy and/or side effects would occur, suggesting that
estimates from our primary analyses were conservative.
In summary, we believe the analytical model developed
here can be of value in considering the cost-effectiveness
of alternative treatments for patients with moderate-to-
severe GAD. Our ﬁndings also suggest that, from a Spanish
perspective, pregabalin may be cost-effective in compari-
son with venlafaxine XR in the treatment of such patients.
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